Drug Approval | March 31, 2026
Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
At the center of the collapse is opposition from the Federal Trade Commission
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Marks first international filing for Evofem’s single-dose oral treatment
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
Subscribe To Our Newsletter & Stay Updated
